Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPD | P32754 | 5/20 | 0.49 |
| ▸ | HTR1A | P08908 | 1/20 | 0.48 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.48 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.48 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | PPIA | P62937 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 3/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.47 |
| ▸ | MGMT | P16455 | 1/20 | 0.47 |
| ▸ | APP | P05067 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | ALPG | P10696 | 1/20 | 0.45 |
| ▸ | PTK2B | Q14289 | 1/20 | 0.45 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30318898 | 1.00 | HPD (0.49) | HPDHTR1AADRA1DADRA1AADRA1B | |
| SCHEMBL15013285 | 0.89 | MAPT (0.55) | HPDHTR1AADRA1DADRA1AADRA1B | |
| SCHEMBL29800426 | 0.85 | HPD (0.45) | HPDHTR1AADRA1DADRA1AADRA1B | |
| SCHEMBL2986814 | 0.84 | HPD (0.57) | HPDPPIAMEN1KMT2AALDH1A1 | |
| SCHEMBL9528862 | 0.83 | HTR1A (0.54) | HPDHTR1AADRA1DADRA1AADRA1B | |
| SCHEMBL29800323 | 0.83 | PTPN1 (0.44) | HPDHTR1AADRA1DADRA1AADRA1B | |
| SCHEMBL6348032 | 0.82 | HPD (0.47) | HPDHTR1AMAPTMAPK1TDP1 | |
| SCHEMBL2892659 | 0.82 | HPD (0.52) | HPDHTR1AADRA1DADRA1AADRA1B | |
| SCHEMBL647866 | 0.82 | TDP1 (0.56) | HPDHTR1AADRA1DADRA1AADRA1B | |
| SCHEMBL29617906 | 0.82 | HPD (0.52) | HPDHTR1AADRA1DADRA1AADRA1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12239643-B2 | Therapeutic agent for inflammatory diseases, autoimmune diseases, fibrotic diseases, and cancer diseases | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2025-03-04 | — | — | US | disclosed |
| US-20230285581-A1 | RIFAMYCIN ANALOGS AND ANTIBODY-DRUG CONJUGATES THEREOF | REGENERON PHARMACEUTICALS, INC. (US) | 2023-09-14 | — | — | US | disclosed |
| US-20230285581-A1 | RIFAMYCIN ANALOGS AND ANTIBODY-DRUG CONJUGATES THEREOF | REGENERON PHARMACEUTICALS, INC. (US) | 2023-09-14 | — | — | US | disclosed |
| US-11666658-B2 | Rifamycin analogs and antibody-drug conjugates thereof | Regeneran Pharmaceuticals, Inc. (US) | 2023-06-06 | — | — | US | disclosed |
| US-11666658-B2 | Rifamycin analogs and antibody-drug conjugates thereof | Regeneran Pharmaceuticals, Inc. (US) | 2023-06-06 | — | — | US | disclosed |
| CN-112351986-B | Crystals of benzoxazole derivative | 明治制果药业株式会社 | 2023-04-18 | — | — | CN | disclosed |
| US-11512091-B2 | Crystal of benzoxazole derivative | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2022-11-29 | — | — | US | disclosed |
| EP-3816167-B1 | CRYSTAL OF A BENZOXAZOLE DERIVATIVE | MEIJI SEIKA PHARMA CO LTD (JP) | 2022-08-03 | — | — | EP | disclosed |
| CN-110114358-B | Novel compound and pharmacologically acceptable salt thereof | 明治制果药业株式会社 | 2021-12-03 | — | — | CN | disclosed |
| EP-3897841-A1 | RIFAMYCIN ANALOGS AND ANTIBODY-DRUG CONJUGATES THEREOF | Regeneron Pharmaceuticals, Inc. (US) | 2021-10-27 | — | — | EP | disclosed |
| CN-101253171-A | Benzooxazole, oxazolopyridine, benzothiazole and thiazolopyridine derivatives | HOFFMANN LA ROCHE (CH) | 2008-08-27 | — | — | CN | disclosed |
| EP-1924579-A2 | BENZOOXAZOLE, OXAZOLOPYRIDINE, BENZOTHIAZOLE AND THIAZOLOPYRIDINE DERIVATIVES | F.HOFFMANN-LA ROCHE AG (CH) | 2008-05-28 | — | — | EP | disclosed |
| US-20070093521-A1 | Benzooxazole, oxazolopyridine, benzothiazole and thiazolopyridine derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 2007-04-26 | — | — | US | disclosed |
| WO-2007025897-A2 | BENZOOXAZOLE, OXAZOLOPYRIDINE, BENZOTHIAZOLE AND THIAZOLOPYRIDINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2007-03-08 | — | — | WO | disclosed |
| EP-1020451-B1 | ANILIDE COMPOUNDS AND DRUGS CONTAINING THE SAME | KOWA CO (JP) | 2005-06-15 | — | — | EP | disclosed |
| US-6797717-B2 | ACYL COENZYME A CHOLESTEROL ACYLTRANSFERASE (ACAT) INHIBITORS | KOWA COMPANY, LTD. (JP) | 2004-09-28 | — | — | US | disclosed |
| US-20030087928-A1 | Novel anilide compounds and drugs containing the same | KOWA COMPANY, LTD., JAPAN | 2003-05-08 | — | — | US | disclosed |
| US-20020099074-A1 | Novel anilide compounds and drugs containing the same | KOWA COMPANY, LTD.,JAPAN | 2002-07-25 | — | — | US | disclosed |
| US-6362208-B1 | ANTICHOLESTEROL AGENT | KOWA COMPANY, LTD. (JP) | 2002-03-26 | — | — | US | disclosed |
| EP-1020451-A1 | NOVEL ANILIDE COMPOUNDS AND DRUGS CONTAINING THE SAME | Kowa Co., Ltd. (JP) | 2000-07-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030087928-A1 | Novel anilide compounds and drugs containing the same | ACAT1, ACAT2, LCAT | HPD 1906/4885HTR1A 4606/4885ADRA1D 770/4885 |
| US-20070093521-A1 | Benzooxazole, oxazolopyridine, benzothiazole and thiazolopyridine derivatives | SSTR5, NPY5R, NPY1R | HPD 1200/4885HTR1A 216/4885ADRA1D 111/4885 |
| US-20020099074-A1 | Novel anilide compounds and drugs containing the same | SOAT1, SOAT2, LCAT | HPD 1941/4885HTR1A 3613/4885ADRA1D 253/4885 |
| US-11666658-B2 | Rifamycin analogs and antibody-drug conjugates thereof | ASGR1, CUTA, SRPRA | HPD 4008/4885HTR1A 1849/4885ADRA1D 2018/4885 |
| US-20230285581-A1 | RIFAMYCIN ANALOGS AND ANTIBODY-DRUG CONJUGATES THEREOF | ASGR1, CUTA, SRPRA | HPD 4008/4885HTR1A 1849/4885ADRA1D 2018/4885 |
| US-11512091-B2 | Crystal of benzoxazole derivative | OXA1L, XDH, CYP4X1 | HPD 279/4885HTR1A 1131/4885ADRA1D 1063/4885 |
| US-12239643-B2 | Therapeutic agent for inflammatory diseases, autoimmune diseases, fibrotic diseases, and cancer diseases | CCR1, SSB, C5 | HPD 1830/4885HTR1A 2390/4885ADRA1D 1559/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.